2. Adapting innovation
for real-world applications
Mesa Biotech makes laboratory-quality molecular testing
accessible, affordable and fast. Users and clinicians are
enabled by getting real-time, actionable test results at
the point-of-care. Our unique patented and patent
pending technology provides a visual qualitative result
in a low-cost, disposable cassette and palm-sized,
convenient reusable dock in 30 minutes or less.
Focused on improving human health first, the Mesa
Biotech proprietary assay design allows for the rapid
development of a
portfolio of tests
for human, animal,
plant, or food
pathogens.
For Medical Use: Many existing technologies lack
either the accuracy or speed to allow physicians to make
real-time treatment decisions. Influenza is a great exam-
ple. Optimization of treatment decisions for patients with
respiratory-related illness when influenza is suspected has
been complicated by the lack of highly sensitive rapid
influenza diagnostic assays for clinical use. Conceptually,
such assays could assist with more accurate antiviral,
antibiotic, and infection control decisions.1
The Mesa
Biotech technology will provide physicians an accurate,
fast, cost effective test that will deliver answers in a single
office visit in 30 minutes or less. With as much as 20% of
the population getting the flu in a given year2
, the
benefit of the Mesa Biotech Flu A/Flu B/RSV test is that it
will provide highly accurate information that clinicians can
use to determine appropriate treatment options, such as
whether to prescribe antibiotics or antiviral drugs.
1
Annals of Emergency Medicine Volume 61, No. : May 2013
2
http://www.webmd.com/cold-and-flu/flu-statistics
Reusable Dock
Disposable
Cassette
3. As Mesa Biotech continues to add menu to its product
offering, tests for additional acute respiratory and gastro-
intestinal infections and sexually transmitted diseases will
be added to the pipeline.
For Agriculture: The Mesa Biotech platform is
versatile. Mesa Biotech has worked closely with the U.S.
Department of Agriculture (USDA) under a grant to
develop a fast, affordable, accurate method for citrus
greening disease, also known as Huanglongbing (HLB), to
replace inefficient, expensive laboratory-based testing
methods. The Agricultural Research Service (ARS) of the
U.S. Department of Agriculture (USDA) says in its 2015
annual report “Early detection will aid in management of
the disease.” It is critical to rapidly and accurately identify
diseases that have the potential to affect and wipe out
crops in order to minimize financial damage and potential
food shortages.
For Animal Health: Accurate, real-time answers can
assist veterinarians in treating companion animals and
pets for infectious diseases, providing real-time results
veterinarians can use for appropriate treatment. Our
technology is equally convenient and accurate for use
with livestock.
For Food Safety: The rapid identification of
food-borne pathogens is a major tool in helping manage
food-borne illness and their associated public heath
concerns. The Mesa Biotech molecular testing technolo-
gy can be adapted as a rapid, accurate way to meet this
growing need. The platform can also be used to identify
food containing genetically modified organism (GMO)
ingredients, which has become an important aspect of
food supply management.
TM
4. Hong Cai, Co-Founder & Chief Executive Officer
• Ph.D. University of Southern California (1995)
• Staff Scientist, Los Alamos National Lab, (1995-09)
• Over 20 years of experience in molecular bioassay development
R. Bruce Cary, Co-Founder & Chief Scientific Officer
• Ph.D. University of Colorado, Boulder (1994)
• Staff Scientist, Los Alamos National Lab (1995-09)
• Over 20 years of nucleic acid array and assay development
William R. Brody, Chairman of the Board
• M.D. and Ph.D. Stanford University
• President, The Salk Institute (2009-2015) and President, The
Johns Hopkins University (1996-2009)
• >100 publications and 2 U.S. patents in the fields of medical
imaging, medical acoustics, computed tomography, digital
radiography, and magnetic resonance imaging
Tom Willardson, Chief Financial Officer
• MBA University of Southern California (1978)
• Former CFO of Sapphire Energy, Aurora Algae, Energy
Recovery, Cost Plus World Market, and WebSideStory
• Over 30 years of finance experience including 3 successful IPOs
Emily Winn-Deen, Chief Strategy Officer
• Ph.D. Boston University, Boston (1978)
• President, RxDx Advisors; Former Vice President, Research
Services, AltheaDx; Vice President, Diagnostics Development,
Illumina; Vice President of Strategic Planning & Business
Development, Cepheid
• Over 30 years of experience in diagnostic product develop-
ment, strategic planning, and business development
John Monroe, Sr. VP of Operations
• BS Biology, San Diego State University
• Former Operations Leader Alere, VP of Technical Operations at
DAKO Corp.
• Over 30 years experience in operations, manufacturing and
production
Executive Team
National Institute of Allergy and
Infectious Diseases
Defense Threat Reduction Agency
US Department of Agriculture California Citrus Research Board NOAA (National Oceanic and
Atmospheric Administration)
Los Alamos National Laboratory
Small Business Assistance Program
6190 Cornerstone Court East, Suite 220
San Diego, CA 92121
Phone: 858-800-4929
Email: Info@mesabiotech.com
For partnership and distribution inquiries, please
contact Emily Winn-Deen
ewinn-deen@mesabiotech.com
For investment inquiries, contact Tom Willardson
twillardson@mesabiotech.com
TM
New Mexico Venture
Acceleration Fund
Bill & Melinda Gates Foundation
Sponsors
